Nebivolol therapy improves QTc and QTcd parameters in heart failure patients
| Autor: | Cagirci G, Sen N, Cay S, Aksoy Sm |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Male
medicine.medical_specialty Treatment outcome Adrenergic beta-Antagonists QT dynamics QT interval Ventricular Function Left Nebivolol Electrocardiography Heart Conduction System Internal medicine medicine Humans Benzopyrans improvement Aged Heart Failure medicine.diagnostic_test business.industry Cardiovascular Topics General Medicine medicine.disease Treatment Outcome Ethanolamines Nebivolol therapy Heart failure Cardiology Platelet aggregation inhibitor Female Electrical conduction system of the heart Cardiology and Cardiovascular Medicine business Platelet Aggregation Inhibitors medicine.drug Follow-Up Studies |
| Zdroj: | Cardiovascular Journal of Africa |
| ISSN: | 1680-0745 |
| Popis: | Aim It has previously been shown that β-blocker therapy reduces QT dynamics in heart failure patients. The aim of this study was to demonstrate this improvement with the third-generation β-blocker, nebivolol. Methods A total of 72 heart failure patients with systolic dysfunction were included in the study. Corrected QT (QTc) and QT dispersion (QTcd) were measured manually by two independent observers at baseline and after nebivolol use (5 mg/day) in the first and third months of follow up. Results Both QTc and QTcd were found to be significantly reduced in the first (455.3 ± 26.7 vs 441.2 ± 25.7 ms, p < 0.001 for QTc, and 65.6 ± 5.3 vs 58.2 ± 5.6 ms, p = 0.001 for QTcd) and third months (455.3 ± 26.7 vs 436.0 ± 28.7 ms, p < 0.001 for QTc, and 65.6 ± 5.3 vs 56.0 ± 6.2 ms, p < 0.001 for QTcd) compared with baseline values. Conclusion Nebivolol was associated with improved QT dynamics in heart failure patients with systolic dysfunction. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|